Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Summary

The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).

Timeline

Start

2021-08-26

Primary completion

2024-07-04

Completion

2024-09-16

Outcome

Outcome not reported

Stopped (Enrollment): “The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.”

Drugs

Indications